moneyheap
LGND · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Ligand Pharmaceuticals Inc. (LGND) stock moving?
Ligand's Q3 2026 results (reported Oct 29) beat consensus on both lines, with adjusted EPS of $2.67 vs $2.38 expected and sales of $78.7M vs $77.2M. Royalty revenue rose 51% year over year to $70.3M and made up 89% of revenue, driven by the XOMA assets, Filspari and Ohtuvayre. Total revenue fell 32% year over year, but the prior year included $53.1M of Pelthos divestiture income; excluding that, revenue rose 26%. Full-year adjusted EPS guidance was raised to $9.50-$9.75 (from $9.00-$9.50, vs $9.30 expected). Benzinga reports that sales guidance was cut to $225M-$250M from $270M-$310M (vs $288.6M expected), but the press release headline says revenue guidance was reaffirmed, so this conflict should be checked against the filing. Analysts followed with higher targets: RBC to $357 (Outperform), Oppenheimer to $346 (Outperform), and Citi maintaining Buy with a $402 target on Nov 5. Other activity includes Ligand's participation in the Pelthos PIPE, a Santen Ryjunea royalty acquisition and a structured financing with AvenCell. On the price side, LGND closed at $314.16 on Nov 10, about 2% above the Oct 22 close of $307.82. It peaked near $325.96 on Nov 2 and fell to $297.63 on Nov 5, and it has held in the $306-$316 range since. Volume has eased to 133k-172k shares over the last three sessions, down from 250k-370k on the earlier sell-off days. A Nov 4 insider sale of about $1.57M is a mild negative. The next key catalyst is the Dec 8 investor day, where management will share a five-year outlook.
News behind the analysis
- Citigroup Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $402Citigroup kept its Buy rating on Ligand and raised its price target to $402. The target sits about 28% above the Nov 10 close of $314.16.
- Ligand Pharmaceuticals Insider Executes Stock SaleAn insider sold Ligand shares worth about $1.57 million, according to a recent SEC filing. The filing does not indicate a broader change in insider sentiment.
- Ligand Pharmaceuticals Participates in Pelthos Therapeutics PIPE FinancingLigand is named as a PIPE investor in the financing tied to Pelthos Therapeutics' merger with Castle Creek Biosciences. The deal involves 5.2 million shares plus up to $300 million in milestones.
- RBC Capital Maintains Outperform on Ligand Pharmaceuticals, Raises Price Target to $357RBC kept its Outperform rating and raised its price target to $357 from $345. The target is about 14% above the Nov 10 close.
- Oppenheimer Adjusts Price Target on Ligand Pharmaceuticals to $346 From $334Oppenheimer raised its price target on Ligand to $346 from $334 and kept an Outperform rating. The target is about 10% above the Nov 10 close.
- Ligand Reports Third Quarter 2026 Financial ResultsRoyalty revenue rose 51% year over year to $70.3M, and adjusted diluted EPS guidance was raised to $9.50-$9.75. Total revenue fell 32% to $78.7M because the prior year included $53.1M of Pelthos divestiture income.
- Ligand Pharmaceuticals Raises FY2026 Adj EPS Guidance from $9.00-$9.50 to $9.50-$9.75 vs $9.30 Est; Lowers FY2026 Sales Guidance from $270.000M-$310.000M to $225.000M-$250.000M vs $288.592M EstBenzinga reports a higher adjusted EPS guide and a lower sales guide than consensus. The press release headline says revenue guidance was reaffirmed, so the sales change needs checking against the filing.
- Ligand Pharmaceuticals Q3 Adj. EPS $2.67 Beats $2.38 Estimate, Sales $78.700M Beat $77.232M EstimateQ3 adjusted EPS of $2.67 beat the $2.38 estimate, and sales of $78.7M beat the $77.2M estimate. Both figures topped consensus.
- Ligand Pharmaceuticals Q3 2026 Earnings Call TranscriptThe transcript of the Q3 2026 earnings call, held the day results were released, is now available. It covers the royalty growth and guidance discussed in the press release.
About Ligand Pharmaceuticals Inc.
Ligand Pharmaceuticals, based in Jupiter, Florida, buys and holds rights to royalties on drugs developed and sold by other biopharma companies, rather than selling its own medicines. After buying XOMA Royalty in mid-2026, it holds a stake in more than 200 drug assets across many therapy areas and partners. It also earns money from Captisol, its own drug-formulation technology.
How it makes money
Most revenue comes from royalties, which are a percentage of partners' drug sales. Key sources include Travere's Filspari, Pelthos's Zelsuvmi, and Merck's Ohtuvayre and Capvaxive. Royalties made up roughly 80% of first-half 2026 revenue (about $91M of $115M). The rest comes from selling Captisol, a formulation ingredient, and from milestone and license payments. Ligand also funds other companies' drug development in exchange for future royalties, as in its 2026 deal with AvenCell. Its guidance for 2026 total revenue is roughly $270–310M.
What usually moves LGND
- Sales growth of key royalty drugs like Filspari
- Partners' clinical trial readouts and FDA approvals
- Royalty acquisitions such as the XOMA deal
- Captisol demand and customer mix
- Guidance changes and financing terms